Cancer Research Technology
Log in Register
Menu

HCT 116 AXL KO Tet-inducible Cell Line

Invented at Queen's University Belfast

Info

Catalogue Number 153206
Antigen/Gene or Protein Targets AXL
Parental Line HCT 116
Host Human
Tissue Colon
Disease Keywords Colorectal cancer
Model Knock-Out
Relevance Receptor tyrosine kinase (RTK) screens identifed AXL as a protein which underpins the migratory/invasive phenotype in colorectal cancer (CRC) (Dunne et al., 2014). AXL was shown to be a poor prognostic marker and an important mediator of cell migration/invasiveness. The HCT 116 AXL KO Tet-inducible cell line enables further investigation into the target as a prognostic biomarker and therapeutic target.
Production Details HCT 116 cells were transfected with pTRIPZ plasmid encoding Tet-inducible shRNA against AXL. Stably transfected cells were selected, maintained in mediumsupplemented with 0.5μg/mL puromycin and induced with 2μg/ml doxycycline.
Conditional Yes
Conditional Description Conditional knockdown of endogenous AXL expression upon treatment with Tetracycline
Research Area Cancer, Cell Structure and Motility, Drug Discovery & Development
Growth/Phenotype Keywords Invasion, migration
Recommended Growing Conditions McCoy’s 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 μg/ml streptomycin
Cellosaurus ID CVCL_HG04

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.

Europe PMC ID: 24170546


Add a reference

References: 2 entries

Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor